| NCT06990399 | A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK | RECRUITING | PHASE3 | 2025-07-30 | 2027-07 | 2026-02 |
| NCT06996080 | A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLE | RECRUITING | PHASE3 | 2025-07-16 | 2027-07 | 2026-12 |
| NCT06556368 | A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK | RECRUITING | PHASE3 | 2024-08-23 | 2027-04 | 2026-04 |
| NCT06270836 | A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Diabetic Retinopathy (DR) | ACTIVE_NOT_RECRUITING | PHASE3 | 2024-05-01 | 2026-01-31 | 2026-01-31 |
| NCT05066230 | A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Non-proliferative Diabetic Retinopathy (NPDR) | TERMINATED | PHASE3 | 2021-09-07 | 2023-08-31 | 2023-08-03 |
| NCT04964089 | A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) | COMPLETED | PHASE3 | 2021-06-23 | 2023-04-06 | 2023-03-28 |
| NCT04611152 | A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME) | TERMINATED | PHASE3 | 2020-09-30 | 2023-08-31 | 2023-05-11 |
| NCT04603937 | A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME) | TERMINATED | PHASE3 | 2020-09-30 | 2023-08-31 | 2023-04-27 |
| NCT04592419 | A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO) | COMPLETED | PHASE3 | 2020-09-25 | 2023-01-19 | 2022-06-10 |
| NCT04049266 | A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration. | TERMINATED | PHASE2, PHASE3 | 2019-10-08 | 2022-04-26 | 2021-11-17 |
| NCT03790852 | Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokinetics Following Single and Multiple Intravitreal Administrations of KSI-301 in Subjects With wAMD, DME and RVO | TERMINATED | PHASE1 | 2018-12-26 | 2022-06-09 | 2021-06-02 |